Clinical Translational Research Award

Investigators at all academic levels (or equivalent)

• Supports the acceleration of innovative preclinical research with a high potential for direct clinical translation that will result in substantial improvements over current approaches to breast cancer chemoprevention and/or therapy
• Must have a clinical trial with at least 1 year of patient accrual within the lifetime of the award
• Preliminary data is required
• Preproposal is required; proposal submission is by invitation only

• No maximum dollar limit for up to 5 years
• No more than $5M will be granted within any single year during the lifetime of the award

Era of Hope Postdoctoral Award

Doctoral graduates (PhD or MD)

No more than 2 years in the proposed research setting and no more than 4 years postdoctoral research experience

• Supports exceptionally talented recent doctoral graduates who have the ambition and ability to pursue highly innovative breast cancer work during their postdoctoral training
• Proposed research should be innovative and challenge current scientific dogma
• Nomination letter is required; proposal submission is by invitation only

Era of Hope Scholar Award

Independent, non-mentored investigators within 6 years of their last mentored position as of the nomination deadline

• Supports exceptionally talented, creative early-career scientists who have demonstrated that they are the "best and brightest" in their fields
• Individuals should exhibit strong potential for leadership in the breast cancer community
• Nomination letter is required; proposal submission is by invitation only

HBCU/MI Partnership Training Award

Principal Investigator/Co-investigator(s): HBCU/MI faculty member with doctoral degree

Mentor(s): Must have an established breast cancer research program at the mentoring institution

• Supports two or more faculty-level investigators at an HBCU/MI to acquire mentored training in breast cancer research
• Supports the establishment of a sustainable breast cancer research program at the applicant HBCU/MI
• Proposed research and training should lead to publication(s) and independent breast cancer research funding

Idea Award

Investigators at all academic levels (or equivalent)

• Supports highly innovative, high-risk/high-reward research from all areas of basic, translational, clinical, behavioral, and epidemiological research
• Innovation is the most important review criterion
• No preliminary data required, but proposal should include a sound scientific rationale

• $375K for direct costs for up to 3 years, plus indirect costs as appropriate
• For population-based studies: $650K for direct costs for up to 5 years, plus indirect costs as appropriate

Impact Award

Investigators at all academic levels (or equivalent)

• Supports unique projects or ideas (from small- to large-scale) that possess strong potential to have an unprecedented impact in breast cancer
• Impact is the most important review criterion (innovation is not a criterion)
• Impact may be scientific or clinical and may be short- or long-term

Innovator Award

Investigators at all academic levels (or equivalent)

• Supports visionary individuals with a history of creativity, innovative work, and leadership in any field
• Provides opportunity to pursue novel, visionary, high-risk ideas that could ultimately lead to the eradication of breast cancer
• Nomination letter is required; proposal submission is by invitation only

Predoctoral Traineeship Award (release date: December 18, 2007)

Principal Investigator: Graduate student (PhD or MD/PhD)

Mentor: Must have breast cancer experience, to include current funding and recent publications

• Supports the preparation of promising graduate students studying breast cancer research under the guidance of a designated mentor
• The predoctoral trainee is considered the PI and should write the proposal with appropriate direction from the mentor
• Training program should prepare the trainee for an independent career in breast cancer research

Synergistic Idea Award

Two independent, faculty-level (or equivalent) investigators

• Supports two investigators who address an innovative, high-risk, potentially high-reward breast cancer question from synergistic and complementary perspectives
• Innovation and synergy are the most important review criteria
• No preliminary data required, but proposal should include a sound scientific rationale

• $500K for direct costs for up to 2 years, plus indirect costs as appropriate
• For population-based studies: $850K for direct costs for up to 5 years, plus indirect costs as appropriate